It's officially the end of the road for Covis’ Makena, as the FDA yanked the medicine's accelerated approval a month after the company agreed to pull it from the market. The move was well anticipated.

Objectives: Poor growth after preterm birth is associated with impaired neurodevelopmental outcome. Limited evidence indicates that breast fed infants have improved neurodevelopmental outcomes but ...